Equities Analysts Issue Forecasts for KALV FY2026 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Cantor Fitzgerald issued their FY2026 earnings estimates for KalVista Pharmaceuticals in a report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the specialty pharmaceutical company will post earnings of ($2.90) per share for the year. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share.

A number of other equities research analysts also recently issued reports on the stock. Jones Trading reaffirmed a “buy” rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $24.83.

KalVista Pharmaceuticals Stock Performance

KALV stock opened at $13.09 on Wednesday. KalVista Pharmaceuticals has a one year low of $7.30 and a one year high of $15.50. The company’s fifty day moving average price is $12.29 and its 200-day moving average price is $10.72. The company has a market capitalization of $650.78 million, a PE ratio of -3.60 and a beta of -0.01.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in KALV. Aquatic Capital Management LLC bought a new position in shares of KalVista Pharmaceuticals in the fourth quarter worth about $44,000. Earned Wealth Advisors LLC bought a new position in shares of KalVista Pharmaceuticals in the first quarter worth about $44,000. GAMMA Investing LLC grew its holdings in shares of KalVista Pharmaceuticals by 567.3% in the first quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company’s stock worth $51,000 after purchasing an additional 3,767 shares during the last quarter. CWM LLC grew its holdings in shares of KalVista Pharmaceuticals by 12,636.1% in the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock worth $53,000 after purchasing an additional 4,549 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 5,502 shares during the last quarter.

Insider Activity

In other news, major shareholder Venrock Healthcare Capital Par bought 25,000 shares of KalVista Pharmaceuticals stock in a transaction dated Wednesday, April 9th. The shares were acquired at an average price of $9.42 per share, with a total value of $235,500.00. Following the completion of the purchase, the insider now owns 5,303,985 shares in the company, valued at $49,963,538.70. The trade was a 0.47% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Paul K. Audhya sold 2,776 shares of the company’s stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $32,867.84. Following the completion of the transaction, the insider now owns 106,611 shares in the company, valued at approximately $1,262,274.24. The trade was a 2.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,899 shares of company stock valued at $206,176. 10.50% of the stock is currently owned by company insiders.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).